We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
LyondellBasell (LYB) Unveils Preliminary Guidance for Q2
Read MoreHide Full Article
LyondellBasell Industries N.V. (LYB - Free Report) provided a preliminary guidance for second-quarter 2019 financial results.
For the second quarter, the company expects EBITDA to improve roughly 10-20% sequentially to the range of $1,575 million-$1,675 million. Net income is projected between $1,035 million and $1,080 million. Earnings per share (EPS) is forecast to be between $2.79 and $2.91.
The company stated that North American integrated ethylene margins improved during the second quarter courtesy of lower feedstock costs. Moreover, oxyfuels are witnessing typical seasonal upside. However, margins in the refining business continues to be a headwind.
Notably, the company is providing guidance on a one-time basis related to the tender offer for its ordinary shares that started on Jun 10, 2019 and is slated to expire on Jul 8, 2019.
Shares of LyondellBasell have lost around 21.1% in the past year compared with the industry’s 33.9% decline.
LyondellBasell is on track with the construction of a HDPE plant on the U.S. Gulf Coast that will employ its proprietary Hyperzone PE technology. The facility is scheduled for startup in third-quarter 2019 and will have an annual capacity of 1.1 billion pounds.
Moreover, the A. Schulman buyout doubles the size of LyondellBasell's existing compounding business. It has also created a platform for future growth and enabled the company to reach into additional high-growth markets such as packaging and consumer products, electronics and appliances, building and construction as well as agriculture.
Zacks Rank & Key Picks
LyondellBasell currently carries a Zacks Rank #3 (Hold).
Materion has an expected earnings growth rate of 27.3% for 2019. The company’s shares have gained 20.1% in the past year.
Flexible Solutions has a projected earnings growth rate of 342.9% for the current year. The company’s shares have surged 143.2% in a year’s time.
AngloGold has an estimated earnings growth rate of 90.6% for the current year. Its shares have rallied 125.5% in the past year.
Breakout Biotech Stocks with Triple-Digit Profit Potential
The biotech sector is projected to surge beyond $775 billion by 2024 as scientists develop treatments for thousands of diseases. They’re also finding ways to edit the human genome to literally erase our vulnerability to these diseases.
Zacks has just released Century of Biology: 7 Biotech Stocks to Buy Right Now to help investors profit from 7 stocks poised for outperformance. Our recent biotech recommendations have produced gains of +98%, +119% and +164% in as little as 1 month. The stocks in this report could perform even better.
Image: Bigstock
LyondellBasell (LYB) Unveils Preliminary Guidance for Q2
LyondellBasell Industries N.V. (LYB - Free Report) provided a preliminary guidance for second-quarter 2019 financial results.
For the second quarter, the company expects EBITDA to improve roughly 10-20% sequentially to the range of $1,575 million-$1,675 million. Net income is projected between $1,035 million and $1,080 million. Earnings per share (EPS) is forecast to be between $2.79 and $2.91.
The company stated that North American integrated ethylene margins improved during the second quarter courtesy of lower feedstock costs. Moreover, oxyfuels are witnessing typical seasonal upside. However, margins in the refining business continues to be a headwind.
Notably, the company is providing guidance on a one-time basis related to the tender offer for its ordinary shares that started on Jun 10, 2019 and is slated to expire on Jul 8, 2019.
Shares of LyondellBasell have lost around 21.1% in the past year compared with the industry’s 33.9% decline.
LyondellBasell is on track with the construction of a HDPE plant on the U.S. Gulf Coast that will employ its proprietary Hyperzone PE technology. The facility is scheduled for startup in third-quarter 2019 and will have an annual capacity of 1.1 billion pounds.
Moreover, the A. Schulman buyout doubles the size of LyondellBasell's existing compounding business. It has also created a platform for future growth and enabled the company to reach into additional high-growth markets such as packaging and consumer products, electronics and appliances, building and construction as well as agriculture.
Zacks Rank & Key Picks
LyondellBasell currently carries a Zacks Rank #3 (Hold).
Some better-ranked stocks in the basic materials space are Materion Corporation (MTRN - Free Report) , Flexible Solutions International Inc (FSI - Free Report) and AngloGold Ashanti Limited (AU - Free Report) . These stocks currently sport a Zacks Rank #1 (Strong Buy). You can see the complete list of today’s Zacks #1 Rank stocks here.
Materion has an expected earnings growth rate of 27.3% for 2019. The company’s shares have gained 20.1% in the past year.
Flexible Solutions has a projected earnings growth rate of 342.9% for the current year. The company’s shares have surged 143.2% in a year’s time.
AngloGold has an estimated earnings growth rate of 90.6% for the current year. Its shares have rallied 125.5% in the past year.
Breakout Biotech Stocks with Triple-Digit Profit Potential
The biotech sector is projected to surge beyond $775 billion by 2024 as scientists develop treatments for thousands of diseases. They’re also finding ways to edit the human genome to literally erase our vulnerability to these diseases.
Zacks has just released Century of Biology: 7 Biotech Stocks to Buy Right Now to help investors profit from 7 stocks poised for outperformance. Our recent biotech recommendations have produced gains of +98%, +119% and +164% in as little as 1 month. The stocks in this report could perform even better.
See these 7 breakthrough stocks now>>